Imipramine

證據等級: L5

預測適應症: 7 個

Imipramine: From Depression to Attention Deficit-Hyperactivity Disorder

One-Sentence Summary

Imipramine is a tricyclic antidepressant (TCA) historically used for major depression and nocturnal enuresis, acting primarily by inhibiting norepinephrine and serotonin reuptake in the central nervous system. The TxGNN model predicts it may be effective for Attention Deficit-Hyperactivity Disorder (ADHD), with 1 registered trial and 20 publications currently supporting this direction. The evidence base includes a 2020 meta-review aggregating RCT-level data on antidepressants in pediatric ADHD, alongside multiple historical clinical studies directly examining imipramine in this population.

Quick Overview

Item	Content
Original Indication	Depression, nocturnal enuresis (historical use; no India registration data available)
Predicted New Indication	Attention Deficit-Hyperactivity Disorder (ADHD)
TxGNN Prediction Score	99.90%
Evidence Level	L3
India Market Status	Not marketed
Number of Registrations	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Detailed mechanism of action data is not available in the current evidence pack. Based on clinical literature, imipramine is a tricyclic antidepressant that inhibits the reuptake of norepinephrine (NE) and serotonin (5-HT), increasing their availability at the synapse. This pharmacological profile is mechanistically analogous to atomoxetine — the only non-stimulant medication specifically approved for ADHD — which works primarily through selective NE reuptake inhibition. The TxGNN model’s high prediction score (99.90%) most likely reflects this mechanistic overlap encoded in the knowledge graph.

Historically, imipramine has been used as a second- or third-line treatment option for childhood ADHD, particularly when stimulants are contraindicated or not tolerated. PMID 17078784 (2006) explicitly categorises imipramine alongside desipramine as “nonselective norepinephrine reuptake inhibitors” effective in ADHD, while PMID 18304665 (2008) demonstrated both clinical response and quantifiable EEG changes in ADHD children who failed stimulant therapy but responded to imipramine. A 1996 biomarker study (PMID 9465283) further identified prolonged P300 latency as a predictor of poor imipramine response, suggesting a precision-medicine angle.

Important caveats exist: the 2020 meta-review (PMID 32982805) flagged suicidality risk with antidepressants in pediatric populations, which is a key regulatory and clinical concern. In addition, 290 documented drug-drug interactions represent a significant challenge when co-prescribing with common ADHD comorbidity medications.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT03220308	NA	Completed	103	8-week mindfulness group training for children (8–16 years) with ADHD combined with a parallel mindful parenting program; purely behavioural intervention — no pharmacological arm and no imipramine involvement

Note: No clinical trials directly evaluating imipramine as a pharmacological treatment for ADHD were identified in the current search. The above trial reflects the full scope of registered trials returned and does not provide drug efficacy evidence.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
32982805	2020	Meta-review	Frontiers in Psychiatry	Aggregates RCT-level data on antidepressants (including imipramine class) in children/adolescents across ADHD, OCD, MDD, and enuresis; flags efficacy alongside suicidality risk signal
10790990	1999	Systematic Review	Evidence Report/Technology Assessment	Assesses short- and long-term effectiveness of pharmacological and non-pharmacological ADHD interventions in children and adults; includes TCA evidence
18304665	2008	Clinical Study	International Journal of Psychophysiology	Imipramine produced clinically significant EEG changes in ADHD children who were poor responders to dexamphetamine and ritalin, supporting its role in stimulant-refractory cases
17078784	2006	Clinical Study	Expert Review of Neurotherapeutics	Proposes P300 topography-guided ADHD treatment selection; classifies imipramine and desipramine as nonselective NE reuptake inhibitors with demonstrated ADHD efficacy
9465283	1996	Clinical Study	Clinical EEG	In 17 ADHD children trialled on imipramine after stimulant failure, prolonged P300 latency predicted poor treatment response — first biomarker-response correlation for imipramine in ADHD
15794722	2005	Safety Review	Expert Opinion on Drug Safety	Systematically reviews safety of non-stimulant ADHD agents; positions imipramine and desipramine as options after atomoxetine, with cardiac monitoring requirements highlighted
2258453	1990	Clinical Study	Journal of Clinical Psychopharmacology	Retrospective study in 36 ADHD children showing carbamazepine co-administration significantly lowered imipramine/desipramine plasma levels — a critical PK drug interaction finding
2830919	1988	Clinical Study	Biological Psychiatry	Investigated ³H-imipramine platelet binding in ADHD boys before and after methylphenidate treatment; no difference in binding parameters vs controls, and clinical MPH benefit did not alter binding
14501767	2003	Clinical Review	Journal of Urology	Examined ADHD influence on resolution of urinary incontinence and nocturnal enuresis — directly intersects with imipramine’s approved indication for enuresis in the ADHD population
6849467	1983	Clinical Report	American Journal of Psychiatry	Early clinical report specifically on imipramine use for attention deficit disorder, representing one of the earliest published observations in this indication

India Market Information

Imipramine (DB00458) currently has no registered products in India. No license data is available for this drug.

Safety Considerations

Drug Interactions: The evidence pack documents 290 drug-drug interactions (DDI). Selected clinically significant interactions are listed below:

Severity	Interacting Drug	Clinical Note
Major	Epinephrine	Severe hypertension and cardiac arrhythmia risk; avoid concurrent use
Major	Bupropion	Both agents lower seizure threshold; elevated seizure risk with combination
Major	Lorcaserin	Serotonin syndrome risk via additive serotonergic activity
Major	Dolasetron	Additive QT prolongation; risk of ventricular arrhythmia
Major	Potassium citrate	Urinary alkalinisation reduces imipramine renal clearance, raising plasma levels
Moderate	Clarithromycin	CYP3A4 inhibition may elevate imipramine plasma concentrations
Moderate	Cimetidine	CYP inhibition and reduced hepatic clearance increase imipramine exposure
Moderate	Atropine, Hyoscyamine, Dicyclomine, Glycopyrronium	Additive anticholinergic burden (dry mouth, urinary retention, cognitive effects)
Moderate	Morphine	Additive CNS and respiratory depression
Moderate	Famotidine	Anticholinergic potentiation

Full warnings and contraindications are not available in the current evidence pack. Please refer to the package insert for complete prescribing information.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: Imipramine’s norepinephrine reuptake inhibition mechanism is pharmacologically analogous to the approved ADHD agent atomoxetine, and a body of historical clinical studies — supplemented by a 2020 meta-review aggregating RCT data — documents its use in pediatric ADHD as a second- or third-line option. However, the safety profile (290 DDIs, paediatric suicidality signal, narrow therapeutic index, and QTc concern) demands structured risk management before any expanded use.

To proceed, the following is needed:

Retrieve full mechanism of action documentation from DrugBank or an authoritative product monograph
Obtain complete package insert including contraindications, black-box warnings, and REMS requirements
Conduct India-specific regulatory review: determine whether imipramine can be registered or used off-label under CDSCO frameworks
Perform a formal comparative efficacy analysis against current ADHD standard of care (methylphenidate, atomoxetine, lisdexamfetamine, clonidine)
Develop a paediatric safety monitoring plan covering: suicidality surveillance, baseline and follow-up ECG/QTc monitoring, and weight/growth tracking
Create a drug-drug interaction management protocol, particularly for the 5 major-severity interactions and for common ADHD comorbidity polypharmacy scenarios
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.